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Background. D-dimer is associated with increasing severity of atherosclerosis and with increased risk of a cardiovascular disease
(CVD).MethodsandResults.Tobetterunderstandthisriskfactor,weperformedagenomescanon803(301malesand502females)
Mexican Americans in the San Antonio Family Heart Study (SAFHS). The SAFHS is ideal for the discovery of quantitative trait
loci (QTLs) inﬂuencing CVD because CVD risk factors are prevalent in Mexican Americans of San Antonio and because the study
design involves large families, which is optimal for QTL discovery. D-dimer levels were normalized in our study. We found that
D-dimer levels were heritable, at about 23% heritability (P ≈ .00001). In a linkage analysis employing 432 microsatellite markers,
we found strong evidence of a QTL on chromosome 5p with a lod score of 3.32 at 21 centiMorgans (cM). We also found suggestive
evidence of a QTL on chromosome 2q with a lod score of 2.33 at 207cM. Conclusions. To our knowledge, the putative QTL on
chromosome 5p is novel. The possible QTL on chromosome 2q is discussed in relation to a recent report of linkage of a related
hemostatic factor to the same location. These results warrant further investigation.
1.Introduction
D-dimer arises as the breakdown product of the lysis of
ﬁbrin clots [1]. Studies have found that D-dimer levels are
associated with an increased risk of coronary heart disease
(CHD) [2–8], acute ischemic stroke [9–11], venous throm-
bosis [12], and peripheral arterial disease [13]. Another
study found that D-dimer is also associated with severity of
atherosclerosis, where severity was deﬁned as the number
of plaques detected by ultrasonography of the carotid artery
[14]. The role of D-dimer as an index of functional decline
seems not to be restricted to cardiovascular disease (CVD),
however. Indeed, at least one study has found that D-dimer
is associated with functional decline, as measured by four
diﬀerent indices of functional health and by mortality risk
in the elderly [15].
Despite these results, the role of D-dimer in particular
and of hemostatic factors (HFs) more generally in CVD
pathology is still thought to be poorly deﬁned [16]. One
reason for this pessimistic view is that few studies have
addressedthegeneticarchitectureofD-dimerbiology.Ofthe
six studies that report heritability (h2) estimates of D-dimer
levels [17–22], only three reported signiﬁcant heritability
estimates for D-dimer levels, which were 65% in a UK
sample population [18], 33% in a Danish sample population
[21], and 25% in study comprised of sample populations
from the UK and Denmark [22]. In a commentary on the
genetics of HFs, it was argued by Harrap and Hopper that
the genes indicated by the studies on the heritability of
HFs available at the time “...may be bit-players in a much
bigger picture that includes complex genetic control of a
myriad of cardiovascular risk factors and that is clouded
by gene-environment interactions” [23]. It would therefore
seem desirable to establish heritability and then investigate
if the heritability estimate, where signiﬁcant, is underlain
by a quantitative trait locus (QTL) or quantitative trait loci
(QTLs). An excellent example of this approach was provided
by the Spanish team of researchers and their collaborators2 International Journal of Vascular Medicine
cited just above [17]. They moved on from establishing the
heritability of factor XII (FXII) (h2 = 0.67) [17], which is
important in thrombus formation, to demonstrating strong
evidence of putative QTLs for FXII at chromosomes 5 and
2[ 24]. Extending this approach of establishing heritability
and identifying the main QTL or QTLs involved to the
understanding of D-dimer biology would therefore seem
both desirable and feasible.
The work reported here is part of an ongoing research
program on the genetic determinants of CVD in Mexican
Americans participating in the San Antonio Family Heart
Study (SAFHS) [25]. We decided to approach the question
of D-dimer involvement in CVD in the SAFHS from
a statistical genetic perspective to dissect the underlying
genetic architecture of the D-dimer phenotype. The main
goal under this approach is to identify novel functional
genes potentially mediating D-dimer involvement in CVD.
Toward this end, we carried out a multipoint genome scan of
D-dimer levels in Mexican American families participating
in the SAFHS. There are two reasons why we can expect
this approach to be successful. First of all, there is a high
prevalence of CVD risk factors, such as type 2 diabetes and
overweight/obesity, in the Mexican American population of
San Antonio, and, therefore, this population can be said
to be relatively enriched for the genetic and environmental
determinants of CVD [25]. The other reason is that our
particular approach of focusing on large, extended families
is thought to be the optimal design for genome-scan linkage
analyses [25].
2. Methods
2.1. Study Participants and Blood Samples. The SAFHS pop-
ulation is comprised of large Mexican American extended
familiesrandomlyascertainedwithrespecttoCVD[25].The
SAFHS protocols were approved by the Institutional Review
Board at the University of Texas Health Science Center at
San Antonio, and all study participants provided written
informed consent. We analyzed a random subclass of the
larger SAFHS population, where the subclass was comprised
of those individuals who had complete data for D-dimer
levels and selected covariates (see below). We will refer to
this subclass in the ensuing as the sample population. The
pedigree relationships exhibited by the sample population
are reported in Table 1. This information gives an idea of
the extent of genetic information that is both available in the
sample population and useful for the purpose of identifying
QTLs.
Fasting blood samples were obtained from study partic-
ipants at the clinic exam and transported daily on dry ice to
the Southwest Foundation for Biomedical Research (SFBR),
San Antonio, Texas. Plasma and serum were isolated by low-
speed centrifugation, and the buﬀyc o a tw a sh a r v e s t e df o r
DNA extraction.
2.2. Phenotypes and Covariates. Plasma samples were trans-













(ELISA) using 2 monoclonal antibodies against nonoverlap-
ping determinants of D-dimer [26]. D-dimer by this method
has longitudinal within-individual variability comparable to
serum cholesterol [27] and is stable in long-term storage at
−70◦C[ 28]. D-dimer levels were exactly normalized using
the inverse Gaussian transformation.
The covariates used in all analyses were age, sex, age2,
age × sex, age2× sex, oral contraceptive use (i.e., exogenous
hormone use), and menopause status. Age, sex, oral con-
traception, and menopause status are each known to have a
signiﬁcant eﬀect on the risk of CVD in general [29, 30], and,
in some cases, these associations seem related to D-dimer
levels [6–8].
2.3.GenotypesandLinkageAnalysisMethods. DNAextracted
from lymphocytes was used in polymerase chain reactions
(PCRs) for the ampliﬁcation of individual DNA (N =
1339) at 432 dinucleotide repeat microsatellite loci (STRs),
spaced approximately 10 centiMorgan (cM) intervals apart
across the 22 autosomes, with ﬂuorescently labeled primers
from the MapPairs Human Screening set, versions 6 and
8 (Research Genetics, Huntsville, AL). PCRs were per-
formed separately according to manufacturer speciﬁcations
in Applied Biosystems 9700 thermocyclers (Applied Biosys-
t e m s ,F o s t e rC i t y ,C A ) .T h ep r o d u c t so fs e p a r a t eP C R s ,
for each individual, were pooled using the Robbins Hydra-
96 Microdispenser, and a labeled size standard was added
to each pool. The pooled PCR products were loaded into
an ABI PRISM 377 or 3100 Genetic Analyzer for laser-
based automated genotyping. The STRs and standards were
detectedandquantiﬁed,andgenotypeswerescoredusingthe
Genotyper software package (Applied Biosystems).
Mistyping analyses were performed on the preliminary
genotype marker data using Simwalk II, following the
recommendations of the program developers for accounting
for mistyping error by (1) blanking the errant called alleles,
(2) recalling them conditionally on the analysis, or (3)
retypingthemistypedmarkerormarkersasresourcespermit
[31].Ouroverallrateofblankingmistypedmarkersis1.37%.
These mistyping analyses allow investigators to account for
Mendelian errors and spurious double recombinants, both
of which can severely reduce the power of a linkage analysis
if not accounted for [31]. On addressing mistyping error
(by blanking, recalling, or retyping), these genotype dataInternational Journal of Vascular Medicine 3
were then used to compute maximum likelihood estimates
of allele frequencies in SOLAR [32]. Matrices of empirical
estimates of identity-by-descent (IBD) allele sharing at
points throughout the genome for every relative pair were
computed using the Loki package, which uses Markov chain
Monte Carlo methods [33]. The multipoint IBD matrices
are required under our variance components modeling
approach (see below). The Simwalk II and Loki programs
both require chromosomal maps. We used the set of high-
resolution chromosomal maps provided by the research
group at deCODE genetics, Reykjavik, Iceland, which are
availableonlineasasupplementaltabletotheprimaryarticle
[34]. For the identiﬁcation and localization of QTLs, we
performed variance components linkage analyses in SOLAR
[32].
3. Results
The descriptive statistics for the untransformed D-dimer
data are presented in Table 2. Descriptive statistics for the
principal covariates (i.e., not including interactions) of age,
sex, oral contraceptive use, and menopause status are also
reported in Table 2.
The heritability of transformed D-dimer levels in the
sample population is 0.22905 with a standard error of
±0.06792. This maximum likelihood estimate of heritability
is signiﬁcant relative to the null hypothesis of a heritability of
0w i t haP-value ≈ .00001.
Encouraged by the signiﬁcant heritability result for
transformed D-dimer levels, we carried out a multipoint
genome scan. The results of these analyses are reported in
Figure 1. Our genome-wide maximum lod score is 3.32 at
21cM on chromosome 5p15.32–p15.2 in between markers
D5S2505 and D5S807 with 1-lod support interval from
14cMto27cM(Figure 2).Generally,alodscoregreaterthan
3 is deemed signiﬁcant evidence for a putative QTL, and a
lod score greater than 2 is taken to be suggestive evidence of
ap u t a t i v eQ T L[ 25]. In addition to the strong evidence of a
Q T Lo nc h r o m o s o m e5 p ,w ef o u n ds u g g e s t i v ee v i d e n c ef o r
another QTL on chromosome 2q33.2 with a lod score of 2.33
at 207cM (Figure 3).
4. Discussion
We found that D-dimer levels are signiﬁcantly heritable in
the sample population of SAFHS Mexican Americans, with
a heritability of about 23%. As discussed above, there are six
other studies that have reported the heritability of D-dimer
levels [17–22], and only three of these found a signiﬁcant
heritability of D-dimer levels at about 65% in a UK sample
population [18], 33% in a Danish sample population [21],
and 25% in study comprised of sample populations from
the UK and Denmark [22]. The study by Ari¨ ens et al.
analyzed data on 118 monozygotic (MZ) and 112 dizygotic
(DZ) female twins [18]. Bladbjerg et al. also analyzed twin
data on D-dimer levels, and their sample size consisted of
130MZ and 155DZ same-sex twins [21]. Williams et al. also
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Figure 1: Multipoint genome-scan across the 22 autosomes for
D-dimer levels in the San Antonio Family Heart Study. At all
chromosomes, the vertical axis is in lod scores, and the horizontal




































































































































































D-dimer linkage on chromosome 5
Figure 2: Linkage analysis results for D-dimer levels on chromo-
some 5. Axes are as in Figure 1.
sample of 1814 UK female twins (447DZ and 460MZ
pairs) and 398 Danish DZ twins [22]. As regards the other
three, Souto et al. investigated a sample of 397 individuals
from 21 extended pedigrees (12 pedigrees of which required
ascertainmentcorrection)[17],Peetzetal.examined180MZ
and 90DZ (same sex) twins [19], and Vossen et al. analyzed
330 individuals from a large kindred [20]. It is not clear why
D-dimer levels would be heritable in some populations and
not in others. One potential explanation for the discrepancy
in heritability estimation across populations may be that the
studies in which the heritability of D-dimer levels was not
signiﬁcant were relatively more youthful. The mean age in
the Souto et al. study was reported as 37.7 years with a range
from <1t o8 8y e a r so fa g e[ 17]. In the Peetz et al. study, the
MZ twins had a mean age of 32.8 years and the same-sex DZ4 International Journal of Vascular Medicine




Sex Mean age Menopause Oral contraceptives
Male (N = 301) 42.4676 NA NA






















































































































































































































D-dimer linkage on chromosome 2
Figure 3: Linkage analysis results for D-dimer levels on Chromo-
some 2. Axes are as in Figure 1.
twinshadameanageof35.4years[19].Vossenetal.reported
am e a na g eo f3 1 . 3y e a r sw i t har a n g ef r o m1t o9 0y e a r so f
age [20]. Ari¨ ens et al. reported a mean age of about 53 and
52 years, respectively, for the MZ and DZ subsets of twins
[18]. Bladbjerg et al. reported mean ages of 78.1 and 77.9,
respectively, for the MZ and DZ subsets of twins [21]. The
weighted mean age for the study by Williams et al. for mixed
UK and Danish samples is a little over 53 years (calculated
from their Table 1)[ 22]. The mean age in our study, as
reported in Table 2, is about 42.5 and 43.5 years in males and
females, respectively. For the male subset, the range is from
18 to 97 years of age. For the female subset, the range is from
18 to 89 years of age. It may be that both mean age and the
rangeofagesinastudy population haveasigniﬁcanteﬀectin
heritability determination. This is consistent with the well-
known importance of age in relation to the impact of HFs on
CVD risk [29].
We also carried out a genome-scan study of D-dimer
levels in the SAFHS and found a lod score of 3.32 on
chromosome5p15.32–p15.2at21cMnearmarkersD5S2505
andD5S807andalodscoreof2.33onchromosome2q33.2at
207cM. Our ﬁrst signal is thought to be signiﬁcant evidence
of a putative QTL, and the second signal is thought to be
suggestive evidence of another possible QTL. Incidentally,
Soria et al. found evidence of QTLs at chromosomes 5q33
and 2p25, each time at the opposite end of the chromosome
with respect to the current report [24]. In the only other
linkage study of D-dimer levels, Williams et al. reported
lod scores of 3.51 and 2.62 at chromosomes 5q14.1–q21.3
and 14q24.1–q32.13, respectively [22]. We interrogated the
bioinformaticsliteratureforanycandidategenesofrelevance
to hemostasis within the 1-lod interval of the putative QTL
onchromosome5p15butwereunabletoﬁndanysuchgenes.
As for the putative QTL on chromosome 2q33.2, however,
we found from the bioinformatics literature that the gene for
tissue factor pathway inhibitor (TFPI)—TFPI is a Kunitz-
type protease inhibitor that inhibits ﬁbrin clot formation
through regulation of the extrinsic pathway of coagulation—
located nearby at 2q31–q32.1 is an excellent candidate gene.
Regarding the putative QTL on chromosome 5p15.32–
p15.2 reported herein, we note that Sabater-Lleal et al. found
a suggestive lod score of 2.31 at chromosome 5p15.32 for
thrombin-activatable ﬁbrinolysis inhibitor (TAFI), which is
an inhibitor of ﬁbrinolysis [35]. This convergence of our
ﬁnding and of that by Sabater-Lleal et al. is exciting because
together they suggest that the QTL potentially in common
to both studies may be underlain by a novel functional gene
that aﬀects hemostasis.
Although less strong in comparison to our main signal,
the second of our above-mentioned signals is exciting to us
still because a recent report of a linkage analysis of TFPI
by Almasy et al. found a signiﬁcant lod score of 3.52 on
chromosome 2q near marker D2S1384, which is right where
o u rs i g n a lo nc h r o m o s o m e2 qa p p e a r sa n di sn e a r b yt ot h e
structurallocationoftheTFPIgene[36].GiventhatD-dimer
is a degradation product of the breakdown of ﬁbrin clots, the
convergenceofthesignalintheworkofAlmasyetal.andour
chromosome 2q signal is consistent with these QTLs being
underlain by the TFPI gene.
Unfortunately, we did not measure TAFI or TFPI levels.
We are, however, interested in measuring these HFs and
examining their potential relevance to the ﬁndings of this
report. Needless to say, more investigations on the putative
QTL on chromosome 5 and the possible QTL on chromo-
some 2 are warranted.
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